- Home
- BLRX vs APM Comparison
BLRX vs APM Comparison
Compare BLRX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- APM
- Stock Information
- Founded
- BLRX 2003
- APM 2010
- Country
- BLRX Israel
- APM United Kingdom
- Employees
- BLRX N/A
- APM N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- APM Health Care
- Exchange
- BLRX Nasdaq
- APM Nasdaq
- Market Cap
- BLRX 17.1M
- APM 18.9M
- IPO Year
- BLRX 2011
- APM 2018
- Fundamental
- Price
- BLRX $3.47
- APM $1.44
- Analyst Decision
- BLRX Strong Buy
- APM
- Analyst Count
- BLRX 2
- APM 0
- Target Price
- BLRX $19.00
- APM N/A
- AVG Volume (30 Days)
- BLRX 29.9K
- APM 258.0K
- Earning Date
- BLRX 11-24-2025
- APM 12-19-2025
- Dividend Yield
- BLRX N/A
- APM N/A
- EPS Growth
- BLRX N/A
- APM N/A
- EPS
- BLRX N/A
- APM N/A
- Revenue
- BLRX $17,251,000.00
- APM N/A
- Revenue This Year
- BLRX N/A
- APM N/A
- Revenue Next Year
- BLRX N/A
- APM N/A
- P/E Ratio
- BLRX N/A
- APM N/A
- Revenue Growth
- BLRX 1.19
- APM N/A
- 52 Week Low
- BLRX $2.30
- APM $0.46
- 52 Week High
- BLRX $22.60
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- BLRX 37.37
- APM 39.29
- Support Level
- BLRX $3.51
- APM $1.43
- Resistance Level
- BLRX $3.89
- APM $1.50
- Average True Range (ATR)
- BLRX 0.22
- APM 0.10
- MACD
- BLRX -0.05
- APM -0.02
- Stochastic Oscillator
- BLRX 17.85
- APM 14.55
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.